Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 12, Issue 4, Pages 333-338Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2009.35
Keywords
adverse effects; androgen deprivation; estrogen; side effects; testosterone
Categories
Funding
- GTx Inc
Ask authors/readers for more resources
Androgen deprivation therapy (ADT) is the standard of care for metastatic prostate cancer and is increasingly used to treat asymptomatic patients with prostate-specific antigen recurrence after failed primary therapy. Although effective, ADT is associated with multiple adverse effects, many of which are related to the estrogen deficiency that occurs as a result of treatment. These include increased fracture risk, hot flashes, gynecomastia, serum lipid changes and memory loss. By providing clinicians with a greater awareness of the estrogen deficiency induced adverse effects from ADT, they can proactively intervene on the physical and psychological impact these effects have on patients. Prostate Cancer and Prostatic Diseases (2009) 12, 333-338; doi: 10.1038/pcan.2009.35; published online 1 September 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available